These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38402496)
1. Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up. Parodis I; Stephens T; Dominicus A; Eek D; Sjöwall C Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38402496 [TBL] [Abstract][Full Text] [Related]
2. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217 [TBL] [Abstract][Full Text] [Related]
3. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Kandane-Rathnayake R; Louthrenoo W; Hoi A; Luo SF; Wu YJ; Chen YH; Cho J; Lateef A; Hamijoyo L; Navarra SV; Zamora L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Hao Y; Zhang Z; Kikuchi J; Takeuchi T; Basnayake BMDB; Chan M; Ng KPL; Tugnet N; Kumar S; Oon S; Goldblatt F; O'Neill S; Gibson KA; Ohkubo N; Tanaka Y; Bae SC; Lau CS; Nikpour M; Golder V; Morand EF; Arthritis Res Ther; 2022 Mar; 24(1):70. PubMed ID: 35287720 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064 [TBL] [Abstract][Full Text] [Related]
5. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF; Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737 [TBL] [Abstract][Full Text] [Related]
6. Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus. Elefante E; Tani C; Stagnaro C; Signorini V; Parma A; Carli L; Zucchi D; Ferro F; Mosca M Arthritis Res Ther; 2020 Oct; 22(1):241. PubMed ID: 33054823 [TBL] [Abstract][Full Text] [Related]
7. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I Rheumatology (Oxford); 2022 Nov; 61(12):4752-4762. PubMed ID: 35302581 [TBL] [Abstract][Full Text] [Related]
8. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS). Abdelhady EI; Rabie M; Hassan RA Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298 [TBL] [Abstract][Full Text] [Related]
9. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114 [TBL] [Abstract][Full Text] [Related]
10. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus. Golder V; Kandane-Rathnayake R; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Lau CS; Nikpour M; Hoi A; Morand EF; J Rheumatol; 2024 Aug; 51(8):790-797. PubMed ID: 38490668 [TBL] [Abstract][Full Text] [Related]
12. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes. Pawlak-Buś K; Schmidt W; Leszczyński P Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341 [TBL] [Abstract][Full Text] [Related]
13. Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study. Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R Arthritis Res Ther; 2020 Jan; 22(1):8. PubMed ID: 31924267 [TBL] [Abstract][Full Text] [Related]
14. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort. Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948 [TBL] [Abstract][Full Text] [Related]
15. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Nikpour M; Morand EF; Arthritis Res Ther; 2017 Mar; 19(1):62. PubMed ID: 28320433 [TBL] [Abstract][Full Text] [Related]
16. Differential impact of disease activity and damage on health-related quality of life in patients with systemic lupus erythematosus. Riaz MM; Shen L; Lateef A; Cho J Lupus; 2022 Aug; 31(9):1121-1126. PubMed ID: 35676227 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF; Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337 [TBL] [Abstract][Full Text] [Related]
18. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study. Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A; Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484 [TBL] [Abstract][Full Text] [Related]
19. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Piga M; Floris A; Cappellazzo G; Chessa E; Congia M; Mathieu A; Cauli A Arthritis Res Ther; 2017 Nov; 19(1):247. PubMed ID: 29126432 [TBL] [Abstract][Full Text] [Related]
20. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]